BackYD Bio Limited Ordinary Shares Overview

YD Bio Limited Ordinary Shares Receivables

YD Bio Limited Ordinary Shares's receivables is $560K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$558863.00
↑ 936.76% YoYΔ $504958.00 vs prior year quarter

Peer trimmed avg / median

Loading

YD Bio Limited Ordinary Shares Receivables History

Loading

YD Bio Limited Ordinary Shares vs. peers: Receivables Comparison

Loading

YD Bio Limited Ordinary Shares Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

YD Bio Limited Ordinary Shares (YDES) FAQ

As of the most recent data (June 2026), YDES shows a receivables of $560K. That compares with $54K in the prior-year period — up 936.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, YDES's receivables is now $560K (was $54K) — a 936.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether YD Bio Limited Ordinary Shares is outperforming or lagging.

Tracking YDES's receivables over time shows whether YD Bio Limited Ordinary Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $560K That compares with $54K in the prior-year period — up 936.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has YD Bio Limited Ordinary Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $560K) with ownership activity and broader fundamentals.

YD Bio Limited Ordinary Shares's receivables is $560K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.